Cannabis Science Confirms Two Extract-Based Formulations Are Both Available Now at Cannabis Therapeutics & Marisol Therapeuti...
November 30 2011 - 11:51AM
Business Wire
Cannabis Science, Inc. (OTCBB: CBIS), a pioneering US biotech
company developing pharmaceutical cannabis products, is pleased to
announce that the first two Cannabis Science Brand Formulations,
Cannabis Science CT-1 and Cannabis Science MT-1 are now available
at both Cannabis Therapeutics and Marisol Therapeutics exclusively
for Colorado State licensed medical marijuana patients.
Cannabis Science MT-1:
Produced by Marisol Therapeutics: A family-owned shop, Marisol
Therapeutics was founded to assist medical marijuana patients in
obtaining medical marijuana in Colorado. They believe patients have
the right to safe, confidential, quality medical marijuana and
products. They recommend medical marijuana from their own
experience with unrelenting and previously untreatable pain. “We
understand, we care, we want you to heal.” Marisal Therapeutics has
produced a custom blend of but is derived from their proprietary
strains that were developed over 30 years by a Native American
Vietnam veteran in order to address his medical needs. Cannabis
Science CT-1 has been analyzed and shown to be free of insecticides
and molds. The product is produced in soil under organic roof
conditions. ADDRESS: 922 Kimble Drive Pueblo West, CO 81007 PHONE:
719-547-4000 EMAIL: INFO@MARISOLMED.COM and http://marisolmed.com/
for more information.
Cannabis Science CT-1:
Produced by Cannabis Therapeutics was Colorado’s first
dispensary. Working with local law enforcement, state officials,
legal experts, medical physicians, and researchers, Cannabis
Therapeutics sets a standard of both safety and consistent quality
to its members as well as the community at large. Cannabis
Therapeutics is a professional medical business that employs all
its policies and regulations to ensure the most stringent adherence
to the law. Second in importance to legality is implementation of
standardizing techniques to ensure both repeatability in dosing and
quality of medicine. Cannabis Therapeutics began as an organization
built by individuals that did not receive satisfactory relief from
conventional therapies. Cannabis Therapeutics has produced a high
quality cannabis extract from a custom blend of buds hydroponically
grown medical marijuana strains. Cannabis Science CT-1 has been
analyzed and shown to be free of insecticides and molds. ADDRESS:
907 E Fillmore St. Colorado Springs, CO 80907
http://www.cannabistherapeutics.net/ for more information.
The Company has been receiving a constant flow of new inquires
via its website, emails, and telephone calls for cannabis-extract
based medicines. For example, cancer patients seeking a quality,
reproducible extract-based formulations for topical or internal use
have frequently contacted Cannabis Science. In light of the
accumulating anecdotal reports of the successful cancer treatments
with cannabis extracts, the Company will continue to keep patients
updated on current peer-reviewed scientific literature supporting
the historical and modern use of cannabis to treat "tumors”. Unlike
conventional treatment, cannabis medicines have an outstanding
safety profile allowing patients in states with medical marijuana
laws to safely make informed decisions to legally
self-administration of various cannabis-based preparations.
About Cannabis Science, Inc.
Cannabis Science, Inc. is at the forefront of pharmaceutical
grade medical marijuana research and development. The second
formulations will address the needs of patients choosing to use
concentrated cannabis extracts to treat their ailments. Eventually,
all Americans will have access to a safe and effective FDA approved
medicine regardless of which state they live in. To maintain that
marijuana is a dangerous, addictive drug with no medical value is
scientifically absurd. Cannabis medicines, with no effective lethal
dose, are far safer than aspirin, acetaminophen, and most other OTC
drugs that kill thousands of Americans every year.
The Company works with world authorities on phytocannabinoid
science targeting critical illnesses, and adheres to scientific
methodologies to develop, produce and commercialize
phytocannabinoid-based pharmaceutical products. In sum, we are
dedicated to the creation of cannabis-based medicines, both with
and without psychoactive properties, to treat disease and the
symptoms of disease, as well as for general health maintenance.
Forward Looking Statements
This Press Release includes forward-looking statements within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Act of 1934. A statement containing
works such as "anticipate," "seek," intend," "believe," "plan,"
"estimate," "expect," "project," "plan," or similar phrases may be
deemed "forward-looking statements" within the meaning of the
Private Securities Litigation Reform Act of 1995. Some or all of
the events or results anticipated by these forward-looking
statements may not occur. Factors that could cause or contribute to
such differences include the future U.S. and global economies, the
impact of competition, and the Company's reliance on existing
regulations regarding the use and development of cannabis-based
drugs. Cannabis Science, Inc. does not undertake any duty nor does
it intend to update the results of these forward-looking
statements.